Metagenomi Therapeutics (MGX) Liabilities and Shareholders Equity (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $197.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 33.88% year-over-year to $197.0 million; the TTM figure through Mar 2026 stood at $938.3 million (down 31.35% YoY), while the FY2025 annual figure was $221.1 million, down 31.88% from the prior year.
• Liabilities and Shareholders Equity retreated to $197.0 million in Q1 2026 per MGX's latest filing, from $221.1 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $415.4 million in Q1 2024 and bottomed at $197.0 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $308.5 million across 4 years, with a median of $311.2 million in 2024.
• Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity declined 11.03% — and 2026, when it slumped 33.88%.
• Metagenomi Therapeutics' Liabilities and Shareholders Equity stood at $364.8 million in 2023, then declined by 11.03% to $324.6 million in 2024, then slumped by 31.88% to $221.1 million in 2025, then retreated by 10.92% to $197.0 million in 2026.
• Business Quant data shows MGX's Liabilities and Shareholders Equity at $197.0 million in Q1 2026, $221.1 million in Q4 2025, and $247.9 million in Q3 2025.